All about GSK gene therapy deal, Fabry disease treatment

Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

#FDAapproves new treatment for a rare genetic disorder, Fabry disease: https://t.co/LDcousCyWZ. pic.twitter.com/BaWRuc20hC

— FDA Drug Information (@FDA_Drug_Info) August 10, 2018

On Friday, the U.S. Food and Drug Administration approved Amicus's Galafold as the first oral therapy for the rare, sometimes fatal genetic condition in which accumulation of fat damages several organs.

Australia's Nufarm shares plunge 17 percent after Monsanto weedkiller cancer finding

A Californian court finding that a Monsanto weedkiller caused cancer in a school groundskeeper sent shares in an Australian maker of a similar product, Nufarm Ltd, tumbling almost 17 percent to a more than two-year low on Monday. A California jury on Friday found Monsanto liable in a lawsuit filed by a man who alleged the company's glyphosate-based weed-killers caused his cancer and ordered the firm to pay $289 million in damages.

Orchard raises $150 million to expand after GSK gene therapy deal

Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million.

Fresh from hauling in GSK's budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO? - https://t.co/qQz64ruDAZ

— EIPG (@EIPGeu) August 13, 2018

The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)